The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
The industry’s attention still gravitates toward the legacy states. But through operators like SWADE Cannabis…
Metro Boomin and Action Bronson are headlining Puffcon in October, and that alone is worth…
Mary Jane Berlin brought tens of thousands of people into one building and reminded them…
Sacha Baron Cohen has reportedly been filming a new Ali G movie in secret. Could…
Big news for wellness enthusiasts: Canna River, the family-run brand that’s spent years earning trust…
Let's start with the headline nobody in Washington wants to print: marijuana is still illegal.…